DUBLIN, Ireland, August 18, 2026
Cumulus Neuroscience has announced publication of final results from its CNS-102 study in Scientific Reports, providing new evidence that the NeuLogiq® Platform can support longitudinal, at-home cognitive assessment in people living with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Conducted in collaboration with the PRECISIONALS academic-industry initiative hosted by Trinity College Dublin, the eight-month study evaluated the feasibility, usability and performance of combining at-home EEG with multimodal cognitive assessments in patients experiencing significant motor and cognitive impairment.
Study Evaluates Multimodal At-Home Assessment
The CNS-102 study enrolled 28 participants, including 11 people with ALS, seven with FTD and 10 matched healthy controls. Participants completed an eight-month protocol that combined in-clinic neuropsychological assessments at baseline, four months and eight months with NeuLogiq home sessions approximately every two weeks. The approach was designed to address a measurement challenge in ALS–Frontotemporal Spectrum Disorder (ALS-FTSD), where conventional clinical assessments often emphasize motor function while cognitive, behavioral and physiological changes may receive less frequent evaluation. NeuLogiq combines a 16-channel wireless dry-sensor EEG headset with a tablet-based application containing 10 gamified neurocognitive tasks. The assessments cover multiple domains, including executive function, memory, language, social cognition and psychomotor speed, with synchronized EEG recording during selected tasks. According to the study results, participants who completed sessions generated high-quality data, with 92% data completeness within completed sessions overall.The platform also demonstrated strong usability among participants. The ALS group recorded a mean System Usability Scale score of 89, within the good-to-excellent range. In a patient-experience survey, 82% of ALS participants rated the platform as easy to use, while 75% reported a positive or very positive overall opinion of the technology. These findings are notable because ALS can involve substantial physical and bulbar impairment that may make conventional technology-based assessments difficult to complete.
NeuLogiq Detects Cognitive Differences and Exploratory Signals
At baseline, the NeuLogiq digital assessments differentiated the ALS, FTD and control groups, with effect sizes comparable to those observed with the matched clinician-administered neuropsychological battery. This finding suggests that self-administered, gamified digital assessments may be capable of detecting group-level cognitive differences while reducing reliance on frequent in-clinic testing. The researchers also conducted exploratory longitudinal analyses using linear mixed-effects models. These analyses identified group-by-time interactions across four NeuLogiq measures, including signals consistent with changes in the ALS group involving facial-expression recognition and speech fluency. Importantly, the in-clinic neuropsychological battery did not identify statistically significant group-level changes during the same eight-month period. The study authors emphasized that these longitudinal observations are exploratory and should not be considered definitive evidence of disease progression. The relatively small cohort means the findings require replication in larger studies. Nevertheless, the results indicate that more frequent home-based sampling could potentially identify changes that less frequent clinical assessments may overlook.
Advertisement
Digital Endpoints Could Support Future ALS Trials
The publication highlights the potential role of multimodal digital endpoints in future neurodegenerative disease research. ALS and FTD are increasingly viewed as overlapping presentations within the ALS-FTSD spectrum, yet commonly used measures such as the ALS Functional Rating Scale–Revised (ALSFRS-R) primarily capture functional and motor changes. Cumulus said NeuLogiq is designed to complement these measures by providing more frequent assessments of cognition, behavior and neurophysiological activity in participants’ everyday environments. The CNS-102 program was developed with a pre-competitive pharmaceutical consortium involving Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK and Takeda, underscoring potential relevance to future clinical development programs. Participants were recruited through the National ALS Register and clinical appointments at Beaumont Hospital in Dublin. Cumulus said a follow-up publication will report EEG findings from the same cohort. Together, the research could contribute to efforts to develop more sensitive, patient-centered measurements for ALS and FTD clinical trials, while reducing the burden associated with repeated hospital-based assessments.
Source: Cumulus Neuroscience press relese
